HTA Council Recommendation on Bivalent COVID-19 Vaccines as booster

Date of OIC-SOH Approval: 25 April 2023

This assessment followed the HTA Council evaluation framework to evaluate COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability, viability and feasibility; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

Evidence Summary:

HTAC Recommendation Preview:

Policy Question

Should the DOH finance bivalent COVID-19 vaccine Moderna (mRNA-1273.214) [Wild Type (WT) + Omicron BA.1] as 1st, 2nd, and/or 3rd booster dose for priority populations (A1-A3) as part of the 2022 COVID-19 vaccination strategies, to reduce COVID-19 cases, severe infection, and deaths?

Section 2. HTA Council Recommendation (updated as of 11 April 2023)
The HTA Council recommends the use of bivalent COVID-19 vaccine Moderna (mRNA-1273.214) as 1st, 2nd, and/or 3rd booster dose (i.e., 1st, 2nd, 3rd dose after completing the primary series) for adults belonging to the A1 to A3 population groups (healthcare workers; senior citizens; adults with comorbidities, including those with immunocompromising conditions), 4-6 months after the primary series or the last booster dose.

To keep updated on HTA news, visit our website:
Like and follow our FB page: